Alx Oncology Holdings (ALXO) Operating Income (2019 - 2026)
Alx Oncology Holdings recorded quarterly Operating Income of -$19.0 million in Q1 2026, up 17.61% quarter-over-quarter from -$23.0 million in Q4 2025, and up 40.4% year-over-year from -$13.5 million in Q1 2025.
Alx Oncology Holdings' Operating Income history runs 8 years deep, the most recent figure standing at -$19.0 million for Q1 2026.
- In Q1 2026, Operating Income rose 40.4% year-over-year to -$19.0 million; the TTM figure through Mar 2026 stood at -$91.2 million (up 33.22% YoY), while the FY2025 annual figure was -$104.0 million, up 26.99% from the prior year.
- Operating Income came in at -$19.0 million for Q1 2026 at Alx Oncology Holdings, up from -$23.0 million in the prior quarter.
- In the past five years, Operating Income ranged from a high of $88.5 million in Q4 2023 to a low of -$53.3 million in Q3 2023.
- A 5-year average of -$25.1 million and a median of -$32.2 million in 2023 frame the typical range for Operating Income.
- Across the five-year window, Operating Income soared 374.64% in 2023 and plunged 134.6% in 2024, its largest moves.
- Alx Oncology Holdings' Operating Income stood at -$32.2 million in 2022, then soared by 374.64% to $88.5 million in 2023, then slumped by 134.6% to -$30.6 million in 2024, then gained by 24.8% to -$23.0 million in 2025, then gained by 17.61% to -$19.0 million in 2026.
- According to Business Quant data, Operating Income over the past three periods registered -$19.0 million, -$23.0 million, and -$22.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.97 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -15.76 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 642.90 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 268.64 Mn |
| 10 | Alx Oncology Holdings | 189.80 Mn | 49.48 Mn | - | -18.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -18.97 Mn |
| Dec 31, 2025 | -23.02 Mn |
| Sep 30, 2025 | -22.53 Mn |
| Jun 30, 2025 | -26.65 Mn |
| Mar 31, 2025 | -31.82 Mn |
| Dec 31, 2024 | -30.61 Mn |
| Sep 30, 2024 | -32.57 Mn |
| Jun 30, 2024 | -41.53 Mn |
| Mar 31, 2024 | -37.76 Mn |
| Dec 31, 2023 | 88.49 Mn |
| Sep 30, 2023 | -53.28 Mn |
| Jun 30, 2023 | -36.78 Mn |
| Mar 31, 2023 | -32.20 Mn |
| Dec 31, 2022 | -32.22 Mn |
| Sep 30, 2022 | -36.68 Mn |
| Jun 30, 2022 | -33.79 Mn |
| Mar 31, 2022 | -24.75 Mn |
| Dec 31, 2021 | -28.47 Mn |
| Sep 30, 2021 | -24.58 Mn |
| Jun 30, 2021 | -16.30 Mn |
| Mar 31, 2021 | -14.21 Mn |
| Dec 31, 2020 | 16.28 Mn |
| Sep 30, 2020 | -9.81 Mn |
| Jun 30, 2020 | -10.79 Mn |
| Mar 31, 2020 | -5.24 Mn |
| Dec 31, 2019 | -7.73 Mn |
| Sep 30, 2019 | -3.03 Mn |
| Jun 30, 2019 | -4.19 Mn |